Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model

Sandra Palus, Robert Schur, Yoshihiro J. Akashi, Barbara Bockmeyer, Rakesh Datta, Heather Halem, Jesse Dong, Michael D. Culler, Volker Adams, Stefan D. Anker, Jochen Springer

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Cardiac cachexia is a serious complication of chronic heart failure with a prevalence of 10-16% and poor prognosis. There are no current therapy options for cardiac cachexia. Ghrelin is the natural ligand for the GHS-1a-receptor and a potential target for conditions associated with cachexia. Ghrelin has been shown to increase weight in several species. The GHS-1a-receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output. Methods: Human ghrelin or one of two analogues BIM-28125 and BIM-28131 (also known as RM-131) were tested at 50 nmole/kg/d and 500 nmole/kg/d versus placebo in a rat model of heart failure (myocardial infarction). Animals (SD-rats, approx. 225 g at surgery) received diuretics from day 14 and compounds from day 28 for 4 weeks using osmotic pumps. Weight was monitored and body composition analysed (NMR-scanning). Cardiac function was assessed by echocardiography and hemodynamics. Results: Animals with MI gained less weight compared to sham rats until start of the therapy (311 g vs 324 g, p = 0.0129). Animals treated with BIM-28131 at 50 nmole/kg/d or all compounds at 500 nmole/kg/d displayed stronger weight gain compared to placebo and sham (all p

Original languageEnglish
Article numbere26865
JournalPLoS One
Volume6
Issue number11
DOIs
Publication statusPublished - Nov 15 2011

Fingerprint

cachexia
ghrelin
Cachexia
Ghrelin
heart failure
Rats
Heart Failure
Body Weight
Weights and Measures
Animals
body weight
rats
cardiac output
placebos
Placebos
Echocardiography
animals
therapeutics
receptors
diuretics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model. / Palus, Sandra; Schur, Robert; Akashi, Yoshihiro J.; Bockmeyer, Barbara; Datta, Rakesh; Halem, Heather; Dong, Jesse; Culler, Michael D.; Adams, Volker; Anker, Stefan D.; Springer, Jochen.

In: PLoS One, Vol. 6, No. 11, e26865, 15.11.2011.

Research output: Contribution to journalArticle

Palus, S, Schur, R, Akashi, YJ, Bockmeyer, B, Datta, R, Halem, H, Dong, J, Culler, MD, Adams, V, Anker, SD & Springer, J 2011, 'Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model', PLoS One, vol. 6, no. 11, e26865. https://doi.org/10.1371/journal.pone.0026865
Palus, Sandra ; Schur, Robert ; Akashi, Yoshihiro J. ; Bockmeyer, Barbara ; Datta, Rakesh ; Halem, Heather ; Dong, Jesse ; Culler, Michael D. ; Adams, Volker ; Anker, Stefan D. ; Springer, Jochen. / Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model. In: PLoS One. 2011 ; Vol. 6, No. 11.
@article{cbf5931086d24f3bb38e80b52c87b481,
title = "Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model",
abstract = "Cardiac cachexia is a serious complication of chronic heart failure with a prevalence of 10-16{\%} and poor prognosis. There are no current therapy options for cardiac cachexia. Ghrelin is the natural ligand for the GHS-1a-receptor and a potential target for conditions associated with cachexia. Ghrelin has been shown to increase weight in several species. The GHS-1a-receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output. Methods: Human ghrelin or one of two analogues BIM-28125 and BIM-28131 (also known as RM-131) were tested at 50 nmole/kg/d and 500 nmole/kg/d versus placebo in a rat model of heart failure (myocardial infarction). Animals (SD-rats, approx. 225 g at surgery) received diuretics from day 14 and compounds from day 28 for 4 weeks using osmotic pumps. Weight was monitored and body composition analysed (NMR-scanning). Cardiac function was assessed by echocardiography and hemodynamics. Results: Animals with MI gained less weight compared to sham rats until start of the therapy (311 g vs 324 g, p = 0.0129). Animals treated with BIM-28131 at 50 nmole/kg/d or all compounds at 500 nmole/kg/d displayed stronger weight gain compared to placebo and sham (all p",
author = "Sandra Palus and Robert Schur and Akashi, {Yoshihiro J.} and Barbara Bockmeyer and Rakesh Datta and Heather Halem and Jesse Dong and Culler, {Michael D.} and Volker Adams and Anker, {Stefan D.} and Jochen Springer",
year = "2011",
month = "11",
day = "15",
doi = "10.1371/journal.pone.0026865",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFBX in a rat heart failure model

AU - Palus, Sandra

AU - Schur, Robert

AU - Akashi, Yoshihiro J.

AU - Bockmeyer, Barbara

AU - Datta, Rakesh

AU - Halem, Heather

AU - Dong, Jesse

AU - Culler, Michael D.

AU - Adams, Volker

AU - Anker, Stefan D.

AU - Springer, Jochen

PY - 2011/11/15

Y1 - 2011/11/15

N2 - Cardiac cachexia is a serious complication of chronic heart failure with a prevalence of 10-16% and poor prognosis. There are no current therapy options for cardiac cachexia. Ghrelin is the natural ligand for the GHS-1a-receptor and a potential target for conditions associated with cachexia. Ghrelin has been shown to increase weight in several species. The GHS-1a-receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output. Methods: Human ghrelin or one of two analogues BIM-28125 and BIM-28131 (also known as RM-131) were tested at 50 nmole/kg/d and 500 nmole/kg/d versus placebo in a rat model of heart failure (myocardial infarction). Animals (SD-rats, approx. 225 g at surgery) received diuretics from day 14 and compounds from day 28 for 4 weeks using osmotic pumps. Weight was monitored and body composition analysed (NMR-scanning). Cardiac function was assessed by echocardiography and hemodynamics. Results: Animals with MI gained less weight compared to sham rats until start of the therapy (311 g vs 324 g, p = 0.0129). Animals treated with BIM-28131 at 50 nmole/kg/d or all compounds at 500 nmole/kg/d displayed stronger weight gain compared to placebo and sham (all p

AB - Cardiac cachexia is a serious complication of chronic heart failure with a prevalence of 10-16% and poor prognosis. There are no current therapy options for cardiac cachexia. Ghrelin is the natural ligand for the GHS-1a-receptor and a potential target for conditions associated with cachexia. Ghrelin has been shown to increase weight in several species. The GHS-1a-receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output. Methods: Human ghrelin or one of two analogues BIM-28125 and BIM-28131 (also known as RM-131) were tested at 50 nmole/kg/d and 500 nmole/kg/d versus placebo in a rat model of heart failure (myocardial infarction). Animals (SD-rats, approx. 225 g at surgery) received diuretics from day 14 and compounds from day 28 for 4 weeks using osmotic pumps. Weight was monitored and body composition analysed (NMR-scanning). Cardiac function was assessed by echocardiography and hemodynamics. Results: Animals with MI gained less weight compared to sham rats until start of the therapy (311 g vs 324 g, p = 0.0129). Animals treated with BIM-28131 at 50 nmole/kg/d or all compounds at 500 nmole/kg/d displayed stronger weight gain compared to placebo and sham (all p

UR - http://www.scopus.com/inward/record.url?scp=81055144834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055144834&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0026865

DO - 10.1371/journal.pone.0026865

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e26865

ER -